Head and Neck Cancer Drugs Market (By Treatment Type: Chemotherapy, Radiation Therapy, Targeted Therapy, and Immunotherapy; By Sales Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 – 2030
The global head and neck cancer drugs market size was valued at US$ 1.51 billion in 2021 and is expected to reach over US$ 2.99 billion by 2030, poised to grow at a compound annual growth rate (CAGR) of 7.9% from 2021 to 2030.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
A number of malignant tumors that develops around throat, nose, mouth, salivary glands, and larynx. The chemotherapy in addition to other therapies are generally used for the treatment of the head and neck cancer. The rising prevalence of head and neck cancer owing to several factors such as alcohol consumption, tobacco consumption, Epstein-Barr virus (EBV) infection, and human papillomavirus (HPV) infection is significantly driving the demand for the head and neck cancer drugs. It is estimated that around 900,000 cases of neck and head cancer and around 400,000 deaths related to it are recorded annually across the globe. Moreover, males are affected as twice as the females. Therefore, these numbers are the major factors that drive the growth of the global head and neck cancer drugs market. The increasing expenditure by the top market players in the research and development and the availability of the various pipeline drugs such as Atezolizumab, Afatinib, and Ipilimumab are contributing towards the market growth.
The advancements in the non-surgical procedures and therapies such as immunotherapy and targeted therapy are supporting the adoption of the head and neck cancer drugs among the patients across the globe. The availability of advanced diagnostic tools to diagnose the various types of cancer and tumors is supplementing the market growth. The rising awareness among the population regarding the availability of effective and innovative drugs to treat cancer coupled with increasing healthcare expenditure is fueling the head and neck cancer market growth. The rapidly growing biopharmaceutical industry and the rising penetration of the online pharmacies are the major factors that are expected to augment the growth of the market during the forecast period. Moreover, the various developmental strategies such as partnerships, new product launches, and adoption of latest technologies impact the market positively and drive the market growth.
| Report Highlights | Details |
| Market Size by 2030 | USD 2.99 Billion |
| Growth Rate From 2021 to 2030 | 7.9% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Treatment, Sales Channel, Region |
| Companies Mentioned | AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Fortress Biotech, Inc, F. Hoffmann-La Roche Ltd., Immutep Limited, Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer Inc. |
Based on the treatment type, the chemotherapy accounted for the largest market share in 2020. This is attributed to the increased adoption of the chemotherapy along with the radiation therapy and rise in awareness regarding the combination therapies to treat head and neck cancer. There are several drugs such as, capecitabine, cetuximab, paclitaxel, bleomycin, hydroxyurea, and docetaxel are approved for the treatment of head and neck cancer across the globe. Therefore, the rising prevalence of head and neck cancer and increased usage of chemotherapy in combination with different other therapies has fostered the growth of this segment in the past few years.
The immunotherapy is estimated to be the fastest-growing segment during the forecast period. The rising awareness among the patients regarding the effectiveness and the benefits of immunotherapy over the chemotherapy is expected to boost the growth of this segment. The growing focus of the manufacturers and the active participation of the authorities like FDA and EMA in the approval of the immunotherapy drugs is expected to augment the demand for the immunotherapy drugs for the treatment of head and neck cancer.
The retail pharmacies segment accounted 60% revenue share in 2020. This is attributed to the increased penetration of the retail pharmacies and various popular chains of pharmacies across the globe. Retail pharmacies are the traditional and the most popular type of sales channel among the population for buying drugs. Therefore, the increased coverage of the retail pharmacies from urban to rural areas across the globe has fostered the growth of this segment.
The online pharmacies segment is expected to be the fastest-growing segment during the forecast period. The rising penetration of internet and growing adoption of smartphones are the major factors that boost the growth of the online pharmacies. According to the International Telecommunication Union, approximately 4 billion people had access to the internet in 2019 and the majority of the people were accessing to the internet using their smartphones. Furthermore, the growing popularity of the online retail platforms across the globe is driving the growth of this segment.
North America dominated the global head and neck cancer market in 2020. According to the American Cancer Society, head and neck cancer accounts for around 4% of the total cancer cases in US. In 2021, it is estimated that around 48,740 men and 17,890 women will develop head and neck cancer. Around 14,620 deaths are estimated to occur in US in 2021 due to head and neck cancer. Therefore, the rising prevalence of head and neck cancer is driving the growth of the head and neck cancer drugs market in North America. The presence of sophisticated healthcare infrastructure, increased healthcare expenditure, favorable reimbursement policies, enhanced access to the advanced diagnostic devices are the major factors that drives the growth of the head and neck cancer drugs market in North American region.
Asia Pacific is estimated to be the most opportunistic market during the forecast period. This can be attributed to the presence of huge population, rising prevalence of head and neck cancer owing to the rising prevalence of smoking, rising alcohol consumption, and rising tobacco consumption, rising awareness regarding the availability of innovative drugs, and rising healthcare expenditure. The rising consumer awareness towards the early diagnosis of cancer and rising demand for the advanced therapeutics is significantly fostering the market growth in this region.
Key Companies & Market Share Insights
The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.
The various developmental strategies like new product launches, acquisitions, and mergers fosters market growth and offers lucrative growth opportunities to the market players.
Segments Covered in the Report
By Treatment Type
By Sales Channel
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Head and Neck Cancer Drugs Market
5.1. COVID-19 Landscape: Head and Neck Cancer Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Head and Neck Cancer Drugs Market, By Treatment
8.1. Head and Neck Cancer Drugs Market, by Treatment Type, 2021-2030
8.1.1. Targeted Therapy
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Chemotherapy
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Radiation Therapy
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Immunotherapy
8.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Head and Neck Cancer Drugs Market, By Sales Channel
9.1. Head and Neck Cancer Drugs Market, by Sales Channel, 2021-2030
9.1.1. Retail Pharmacies
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Hospital Pharmacies
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Head and Neck Cancer Drugs Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.1.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.1.3.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.1.4.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.3.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.4.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.5.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.2.6.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.3.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.4.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.5.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.3.6.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.3.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.4.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.5.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.4.6.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.5.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.5.3.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment (2019-2030)
10.5.4.2. Market Revenue and Forecast, by Sales Channel (2019-2030)
Chapter 11. Company Profiles
11.1. AstraZeneca PLC
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Bristol-Myers Squibb Company
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Eli Lilly and Company
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Fortress Biotech, Inc
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. F. Hoffmann-La Roche Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Immutep Limited
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Merck & Co., Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Merck KGaA
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Novartis AG
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Pfizer Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
